Johnson & Johnson Inventory 2012-2026 | JNJ
Johnson & Johnson inventory from 2012 to 2026. Inventory can be defined as the total value of inventories in all stages of completion.
- Johnson & Johnson inventory for the quarter ending March 31, 2026 was $14.191B, a 14.04% increase year-over-year.
- Johnson & Johnson inventory for 2025 was $14.191B, a 14.04% increase from 2024.
- Johnson & Johnson inventory for 2024 was $12.444B, a 11.3% increase from 2023.
- Johnson & Johnson inventory for 2023 was $11.181B, a 8.89% increase from 2022.
|
Johnson & Johnson Annual Inventory (Millions of US $) |
|
|---|---|
| 2025 | $14,191 |
| 2024 | $12,444 |
| 2023 | $11,181 |
| 2022 | $10,268 |
| 2021 | $10,387 |
| 2020 | $9,344 |
| 2019 | $9,020 |
| 2018 | $8,599 |
| 2017 | $8,765 |
| 2016 | $8,144 |
| 2015 | $8,053 |
| 2014 | $8,184 |
| 2013 | $7,878 |
| 2012 | $7,495 |
| 2011 | $6,285 |
|
Johnson & Johnson Quarterly Inventory (Millions of US $) |
|
|---|---|
| 2025-12-31 | $14,191 |
| 2025-09-30 | $14,146 |
| 2025-06-30 | $13,412 |
| 2025-03-31 | $12,659 |
| 2024-12-31 | $12,444 |
| 2024-09-30 | $12,603 |
| 2024-06-30 | $12,169 |
| 2024-03-31 | $11,383 |
| 2023-12-31 | $11,181 |
| 2023-09-30 | $11,198 |
| 2023-06-30 | $12,888 |
| 2023-03-31 | $12,809 |
| 2022-12-31 | $10,268 |
| 2022-09-30 | $11,675 |
| 2022-06-30 | $11,437 |
| 2022-03-31 | $10,990 |
| 2021-12-31 | $10,387 |
| 2021-09-30 | $10,387 |
| 2021-06-30 | $10,100 |
| 2021-03-31 | $9,952 |
| 2020-12-31 | $9,344 |
| 2020-09-30 | $9,599 |
| 2020-06-30 | $9,424 |
| 2020-03-31 | $8,868 |
| 2019-12-31 | $9,020 |
| 2019-09-30 | $9,173 |
| 2019-06-30 | $9,263 |
| 2019-03-31 | $9,086 |
| 2018-12-31 | $8,599 |
| 2018-09-30 | $8,678 |
| 2018-06-30 | $8,810 |
| 2018-03-31 | $9,014 |
| 2017-12-31 | $8,765 |
| 2017-09-30 | $9,521 |
| 2017-06-30 | $9,699 |
| 2017-03-31 | $8,878 |
| 2016-12-31 | $8,144 |
| 2016-09-30 | $8,488 |
| 2016-06-30 | $8,523 |
| 2016-03-31 | $8,170 |
| 2015-12-31 | $8,053 |
| 2015-09-30 | $8,206 |
| 2015-06-30 | $8,298 |
| 2015-03-31 | $8,085 |
| 2014-12-31 | $8,184 |
| 2014-09-30 | $8,419 |
| 2014-06-30 | $8,155 |
| 2014-03-31 | $8,009 |
| 2013-12-31 | $7,878 |
| 2013-09-30 | $8,124 |
| 2013-06-30 | $7,822 |
| 2013-03-31 | $7,691 |
| 2012-12-31 | $7,495 |
| 2012-09-30 | $7,809 |
| 2012-06-30 | $7,697 |
| 2012-03-31 | $6,800 |
| 2011-12-31 | $6,285 |
| 2011-09-30 | $6,428 |
| 2011-06-30 | $6,413 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |